In a recent study led by Soman Abraham from Duke University, investigators observed that an increase in nociceptive sensory nerves in urinary tract biopsies from patients with recurrent urinary tract infections (rUTIs) was linked to elevated nerve growth factor (NGF) from monocytes and mast cells. This overgrowth of nerve cells appeared to cause lingering symptoms after rUTIs. These findings, appearing in the March 1, 2024, online edition of Science Immunology, have the potential to provide a new approach to managing symptoms of rUTIs that would reduce unnecessary antibiotic usage. Read More
Iron-sulfur clusters are co-factors that are involved in several biological processes, such as oxidative phosphorylation, enzymatic reactions, and DNA replication and repair. Scientists from the National Institutes of Health (NIH) have presented a study regarding the clinical manifestations associated with a novel neuromuscular disease gene – CIAO1 – which encodes probable cytosolic iron-sulfur protein assembly protein CIAO1 and is an essential member in the cytoplasmic iron-sulfur assembly machinery. Read More
CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has announced an award of $1.06 million to the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) to develop a new class of small-molecule inhibitors of bacterial sliding clamp (DnaN), a pivotal component of DNA replication machinery, which is a clinically unproven but promising novel mechanism for targeting bacteria. Read More
Crossbow Therapeutics Inc. has nominated its first development candidate, CBX-250, a first-in-class, potent and specific T-cell engager (TCE) for the treatment of myeloid leukemia. CBX-250 targets a cathepsin G (CTSG) peptide-human leukocyte antigen (pHLA) complex abundantly expressed on leukemic cells, but not on normal cells. Read More
Discover a wealth of industry insights with BioWorld’s extensive collection of infographics, covering the latest trends and developments in both biopharma and med-tech. Our weekly infographics are curated to provide concise summaries of key topics: financings (IPOs, private financings, public/other and follow-on offerings), deals and M&As (top deals, and monthly value and volume), regulatory (including U.S. FDA and worldwide approvals), clinical trials and more. In addition, you’ll find access to BioWorld’s year-in-review reports, as well as special infographics about obesity, pain and addiction, biosimilars and the aging space. Read More
The long-term use of corticosteroids for treating Duchenne muscular dystrophy (DMD) is tied to several undesired effects, compromising the patient’s quality of life; hence, the use of nonsteroidal drugs is highly desirable in the treatment of DMD. Metriopharm AG is investigating the nonsteroidal drug MP-1032 for DMD and recently presented data from studies in a model of DMD. Read More
Bristol Myers Squibb Co. has identified tetrazole derivatives acting as diacylglycerol kinase α (DGK-α; DGKA) and/or diacylglycerol kinase ζ (DGK-ζ; DGKZ) inhibitors reported to be useful for the treatment of cancer and viral infections. Read More
Monopar Therapeutics Inc. has released promising preclinical imaging data of a therapeutic radioisotope bound to its proprietary urokinase plasminogen activator receptor (uPAR)-targeting agent, MNPR-101. Read More
Paraneoplastic syndromes are a group of disorders associated with tumors that are prevalent in patients with lymphatic, lung, ovarian or breast cancers. Read More
Nuvalent Inc. has disclosed new heteroaromatic macrocyclic ether compounds acting as proto-oncogene tyrosine-protein kinase ROS (ROS1; MCF3) and/or ALK tyrosine kinase receptor inhibitors potentially useful for the treatment of cancer. Read More
Sonata Therapeutics Inc. and the Champalimaud Foundation have announced a research collaboration for the development of Sonata’s SNT-3012 for the treatment of pancreatic and colorectal cancers. Read More
China State Institute of Pharmaceutical Industry and Jiangsu Nhwa Pharmaceutical Co. Ltd. have jointly described aromatic heterocyclic cyclohexyl aminoalkyl piperidine derivatives acting as serotonin 5-HT1A and/or dopamine D2 and/or D3 receptor agonists reported to be useful for the treatment of Parkinson’s disease. Read More
The company will use its proprietary global phage atlas, developed with support from the Gates Foundation and the National Institutes of Health (NIH). Read More
Additional early-stage research and drug discovery news in brief, from: Elixirgen Therapeutics, Paratek Pharmaceuticals, Tonix Pharmaceuticals. Read More
